[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-response":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,45,70,98,130,154,185,209,232,260,281,318,341,365,387,404,430,458,485,510],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100506542","correlation-of-memory-cd8-t-cells-with-sepsis-severity-and-mortality-a-single-center-unblinded-prospective-non-interventional-observational-study-100506542",false,"NCT05875740","Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study","Inclusion Criteria:\n\nPatients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and\u002For their family members know and agree to participate in the trial.\n\nExclusion Criteria:\n\nHistory of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as autoimmune diseases such as rheumatoid arthritis and SLE, or hematological malignancies such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received immunosuppressive drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (child-Pugh: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and\u002For their family members refuse to participate in the trial.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Severe sepsis is the most common cause of death among critically ill patients in non-coronary intensive care units (ICU). Sustained excessive inflammation and immune dysfunction have been confirmed to play a key role in organ damage and early death of sepsis patients. Therefore, it is important to reduce excessive inflammatory response mediated by immune cells and pro-inflammatory cytokines in the acute phase of sepsis.\n\nSingle-cell RNA sequencing performed on both septic patients and mice suggest that changes in Tcm (CD3+ CD8+ CD44+ CD127+ CD62L+) and Tem (CD3+ CD8+ CD44+ CD127+ CD62L -) in the acute phase of sepsis may play an important role in sepsis. In addition, animal researches showed that Tcm and Tem decreased decreased continuously at 24, 48 and 72h after cecal ligation and perforation (CLP) in mice, and the adoptive transfer of Tcm , sorting from spleen of mice 24h after CLP , but not Tem improved 7-day survival rate of sepsis mice.\n\nThis observational study is aimed to investigate the quantity and proliferation of Tcm and Tem in the acute phase of sepsis and their correlation with severity level and mortality of septic patients in ICU.",[25,26],"Sepsis","Inflammatory Response",[28,29,30,31],"sepsis","CD8+ T cell","central memory CD8+ T cell","inflammatory response","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2023-09-06",{"date":40,"type":21},"2026-09-30",{"name":42,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100636526","velocity-based-resistance-training-effects-on-inflammation-in-older-adults-100636526","NCT07566832","Velocity-Based Resistance Training Effects on Inflammation in Older Adults","Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults","Inclusion Criteria:\n\n* Aged 60-75 years or older\n* No regular resistance training habit (defined as ≥2 sessions per week) in the past year\n* No musculoskeletal injuries within the past six months\n\nExclusion Criteria:\n\n* Obesity (BMI \\> 30 kg\u002Fm²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.\n* Regular use of anti-inflammatory medications (e.g., NSAIDs).\n* Smoking or alcohol abuse\n* Inability to safely perform the prescribed resistance exercise movements\n* Unable to fully comprehend the study information and instructions.","75 Years",{"count":54,"type":21},60,"INTERVENTIONAL",[57],"NA","This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.",[60,26],"Aging","2026-05-04",{"date":63,"type":36},"2026-05-08",{"date":65,"type":36},"2026-04-20",{"date":67,"type":21},"2029-12",{"name":69,"class":43},"National Taipei University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":15,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":55,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100627708","phase-2-endotoxin-exposure-to-examine-the-role-of-inflammation-in-alcohol-use-100627708","NCT07452146","Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use","Understanding the Role of Inflammation in Alcohol Use Disorder: An Inflammatory Challenge Using Lipopolysaccharide","Inclusion Criteria (AUD Group):\n\n1. Be between the ages of 21 and 65\n2. Meet current (i.e., past month) DSM-5 diagnostic criteria for moderate to severe AUD\n3. Be non-treatment seeking for AUD\n4. Report drinking at least 28 drinks per week if male (21 drinks per week if female) in the 28 days prior to consent.\n5. Must agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile:\n\n   * Oral contraceptives\n   * Contraceptive sponge\n   * Patch\n   * Double barrier\n   * Intrauterine contraceptive device\n   * Etonogestrel implant\n   * Medroxyprogesterone acetate contraceptive injection\n   * Complete abstinence from sexual intercourse\n   * Hormonal vaginal contraceptive ring\n\nInclusion Criteria (Control Group):\n\n(1) The control group will be age-, sex-, smoking status-, and BMI-matched healthy individuals who drink at or below moderate drinking levels (≤1 drink\u002Fday for females, ≤2 drinks\u002Fday for males) and have no lifetime history of AUD.\n\nExclusion Criteria (All Groups):\n\n1. Have a current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder\n3. Have current moderate to severe depression as indicated by a score of ≥ 21 on the Beck Depression Inventory - II (BDI-II)\n4. Have current suicidal ideation or lifetime history of suicide attempt as reported on the Columbia-Suicide Severity Rating Scale (C-SSRS)\n5. Have a positive urine screen for drugs other than cannabis;\n6. Have clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R)\n7. Have an intense fear of needles or have had any adverse reactions to needle puncture\n8. Be pregnant, nursing, or planning to become pregnant while taking part in the study\n9. Have a body mass index (BMI) greater than 30\n10. Have a medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes, autoimmune or inflammatory disease)\n11. Have clinically significant abnormal EKG\n12. Have \\> Grade 2 laboratory abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\"\n13. Have any other circumstances that, in the opinion of the investigators, compromises participant safety\n14. To participate in the inflammatory challenge, participants must not show any of the following upon arrival to the inflammatory challenge study visit:\n\n    1. BrAC \\> 0.000 g\u002Fdl\n    2. clinical withdrawal (CIWA-R) score ≥ 10\n    3. blood pressure ≤ 90\u002F60 or ≥ 160\u002F120\n    4. resting pulse ≤ 50 beats\u002Fminute or \\> 100 beats\u002Fminute\n    5. temperature ≥ 99.5°F\n    6. recent (past 2 weeks) acute illness or vaccination\n    7. score of 10+ on Physical Sickness Symptoms Assessment","21 Years","65 Years",{"count":80,"type":21},64,[82],"PHASE2","The study design consists of a randomized, double-blind, placebo-controlled study of low dose endotoxin. Individuals with current AUD (n=32) and matched controls without AUD (n=32) will be randomly assigned to receive a single intravenous (I.V.) infusion of either low dose endotoxin (0.8 ng\u002Fkg of body weight) or placebo (same volume of 0.9% saline solution) to determine the acute and protracted role of inflammation in alcohol use.",[85,26,86],"Alcohol Use Disorder","Craving",[88],"Endotoxin","NOT_YET_RECRUITING","2026-04-28",{"date":61,"type":36},{"date":93,"type":21},"2026-06",{"date":95,"type":21},"2028-07",{"name":97,"class":43},"University of California, Los Angeles",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":55,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100560122","daoist-zhanzhuang-and-human-flourishing-100560122","NCT06573034","Daoist Zhanzhuang and Human Flourishing","Standing Like a Tree: Effects and Mechanisms of Daoist Zhanzhuang on Human Flourishing","Z-Flo","Inclusion Criteria:\n\n1. young adults aged between 18 and 25 years old when they enroll;\n2. be willing and available (e.g., intend to remain in Charlotte or the surrounding area or willing to travel to UNCC campus for in person visits) to participate to 12 month study;\n3. able to stand for 30 minutes;\n4. scoring above 18 on the Perceived Stress Scale (moderate stress); and\n5. able to read, speak and understand English.\n\nExclusion Criteria:\n\n1. experience of qigong-related practice in the past 5 years;\n2. reporting regular medication use that directly modulates immune system functioning (e.g., steroids, cytokine inhibitors, high levels of non-steroidal anti-inflammatory medication, chemotherapy, etc.) or sedates the nervous system (e.g., benzodiazepines, anti-epileptics, tranquilizers, etc.) or alters heart rate (e.g., beta blockers, calcium channel blocker, stimulants, etc.);\n3. self-reported illicit drug use in the past 3 months or substance dependence over the past month (e.g., alcohol binge drinking 2+ days\u002Fweek, using tobacco or nicotine products 5+ days\u002Fweek, cannabis and related products 2+ days\u002Fweek, etc.);\n4. physical impairment that does not allow them to stand for 30 mins (e.g., severe obesity, need wheel-chair or equipment to assist with walking, recent injury that limits standing, etc.), and\n5. severe mental health conditions that could prevent regular practice (e.g., hospitalized in the past 12 months for mental health condition).","25 Years",{"count":108,"type":21},120,[57],"This project investigates the impact of Daoist Zhanzhuang (sometimes spelled as Chan Chuang) on human flourishing, and explores the physiological, psychological, and spiritual mechanisms. This study will be a two-arm randomized controlled trial, with mixed-methods and repeated-measures assessment of outcome variables. The two arms will include an active control condition (i.e., sham wall squat) and the Daoist Zhanzhuang condition. Outcome variables will include physiological measures of heart rate variability and inflammatory biomarkers, psychological scales of human flourishing variables, phenomenological interviews of mystical experiences, and daily ecological momentary assessment of human flourishing and mysticism. Randomly assigned into two conditions, 120 participants will complete a three-week intensive practice phase with 9 in-person sessions, followed by a nine-week self-guided practice phase with 4 in-person check-in sessions, and 3 follow-up practice and assessment sessions. Complete assessment (physiological measures, psychological scales, and phenomenological interviews) will be administered at five time points: T1 at about two weeks before the intervention, T2 at the end of the three-week intensive practice, T3 at the end of the 3-month intervention, T4 at the 6-month follow-up, and T5 at the 12-month follow-up. In addition, daily ecological momentary assessment of flourishing variables and practice-induced experiences will be administered daily after the practice for the entire 3-month intervention period.",[112,113,26,114],"Stress, Physiological","Stress, Psychological","Well-Being, Psychological",[116,117,118,119,120],"Human Flourishing","Daoist Zhanzhuang (Chan Chuang)","Heart Rate Variability","Immune Function","Mysticism","2026-04-27",{"date":123,"type":36},"2026-05-01",{"date":125,"type":36},"2024-08-29",{"date":127,"type":21},"2027-07",{"name":129,"class":43},"University of North Carolina, Charlotte",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":15,"sex":16,"minAge":77,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":55,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":44},"100533947","menthol-inflammation-and-nicotine-transition-study-100533947","NCT06232447","Menthol, Inflammation, and Nicotine Transition Study","Effect of Menthol to Non-Menthol Cigarette Switching on Subclinical Inflammatory Biomarkers of Cardiovascular Health: Simulating a Menthol Cigarette Ban","MINT","Inclusion criteria\n\n* Men and women between 21-85 years old\n* Currently uses menthol cigarettes\n* Daily smoking rate of ≥5 cigarettes\u002Fday for ≥1 year\n* Currently own and regularly use an iOS\u002FAndroid smartphone device able to download the LifeData application\n* Able to read and communicate fluently in English\n\nExclusion criteria\n\n* Currently pregnant or breastfeeding\n* Actively trying to quit smoking\n* Current heavy alcohol use\n* Frequent use of non-menthol cigarettes, other smoking products, or illicit substances\n* History of severe medical\u002Fpsychiatric condition or treatment","85 Years",{"count":140,"type":21},68,[57],"This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.",[144,26],"Cigarette Smoking","2026-04-14",{"date":147,"type":36},"2026-04-16",{"date":149,"type":36},"2024-03-26",{"date":151,"type":21},"2027-06",{"name":153,"class":43},"Rosalind Franklin University of Medicine and Science",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":55,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100541934","phase-4-effect-of-influenza-vaccination-after-myocardial-infarction-on-cardiac-inflammatory-response-100541934","NCT06336317","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE - a Randomized, Double-blind, Placebo-controlled, Trial (ELIMINATE Trial)","ELIMINATE","Inclusion Criteria:\n\n* Patients with a diagnosis of non-ST-segment elevation myocardial infarction\n* A finalized coronary PCI\n* Male or non-fertile female subjects ≥18 years. (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)\n* Written informed consent\n* A CCTA can be scheduled within 7 days after PCI\n\nExclusion Criteria:\n\n* Has received influenza vaccination within 6 months\n* Other vaccination planned within 8 weeks (including covid-19 booster doses)\n* Severe allergy to eggs or previous allergic reaction to influenza vaccine\n* Cardiac surgery or staged PCI planned within 8 weeks\n* Coronary stent involving the proximal RCA\n* Suspicion of febrile illness or acute, ongoing infection\n* Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol\n* Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response\n* Inability to provide informed consent\n* Previous randomization in the ELIMINATE trial\n* Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.\n* Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* Atrial fibrillation\n* Uncontrolled chronic inflammatory disease\n* Unable to comply with protocol requirements",{"count":163,"type":21},90,[165],"PHASE4","The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:\n\nDoes influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo.",[168,169,26],"Acute Myocardial Infarction","Cardiovascular Diseases",[171,172,173,174],"Coronary computed tomography angiography","Percutaneous coronary intervention","Influenza vaccine","Non ST-segment elevation myocardial infarction","2026-04-01",{"date":177,"type":36},"2026-04-07",{"date":179,"type":36},"2024-04-24",{"date":181,"type":21},"2027-12",{"name":183,"class":43},"Region Örebro County",3,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":15,"sex":191,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":55,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":44},"100511074","examining-the-role-of-female-endogenous-sex-hormones-in-eccentric-exercise-100511074","NCT05934708","Examining the Role of Female Endogenous Sex Hormones in Eccentric Exercise","Inclusion Criteria:\n\n* 18-35 years of age\n* BMI of 18.5-29.9 as a BMI below or above these cut points results in highly varied menstrual cycle lengths \\[15\\]\n* Not taking contraception or other types of medication that could influence reproductive status\n* Regular menstruation\n* Non-pregnant\n* Medically free from chronic diseases\n* Novel to downhill running\n* Weight greater than or equal to 110 lbs\n* Not taking exogenous hormones\n* Not suffering from known gynecological disease (i.e., PCOS, endometriosis, etc.) that may influence menstrual cycle regularity\n\nExclusion Criteria:\n\n* Amenorrhea or oligomenorrhea\n* Perimenopausal or menopausal\n* Recreational or professional trail or downhill runner\n* On a form of contraception\n* Cardiac disability\n* Pacemaker\n* Arterial disease\n* Uncontrolled hemorrhage\n* Blood clots\n* Pregnant or trying to become pregnant\n* Cancerous lesions\n* Sensory or mental impairment\n* Unstable fractures\n* Weight less than 110 lbs\n* Suffering from gynecological disease (i.e., PCOS, endometriosis, etc.) that may influence menstrual cycle regularity\n* Taking exogenous hormones","FEMALE","35 Years",{"count":20,"type":21},[57],"The fluctuating concentrations of female sex hormones, namely estrogen and progesterone may have an effect on the ability of the tissue to withstand challenging exercise conditions, such as eccentric exercise. These sex hormones have also been purported to influence the perceived difficulty of exercise. This study aims to uncover how the different estrogen and progesterone concentrations present throughout the menstrual cycle effect perceived readiness to perform, perceptions of difficulty, and different recovery metrics.",[26],[198,199],"menstrual cycle","exercise","2026-03-24",{"date":202,"type":36},"2026-03-25",{"date":204,"type":36},"2025-03-07",{"date":206,"type":21},"2026-08",{"name":208,"class":43},"University of Southern California",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":55,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":44},"100474538","association-between-body-composition-and-pain-in-spinal-cord-injury-100474538","NCT05459207","Association Between Body Composition and Pain in Spinal Cord Injury","Association Among Body Composition, Chronic Pain, Evoked Pain Sensitivity, and Adiposity-related Systemic Inflammation in Individuals With Spinal Cord Injury","Inclusion Criteria:\n\n* Age 18-70 years\n* Spinal cord injury occurring at least 2 years prior to study entry\n* Neurological level of injury (LOI) between C4 and L2\n* American Spinal Injury Association Impairment Scale (AIS) A-D\n* English-speaking.\n\nExclusion Criteria:\n\n* Cognitive dysfunction that limits ability to adequately understand the risks of the study or are otherwise unable to consent\n* Health conditions associated with chronic systemic inflammation unrelated to weight or adiposity (e.g., systemic autoimmune diseases, recurrent or active urinary tract infection, pressure injury \\> Stage 2)\n* Conditions that preclude measurement of body composition by dual-energy x-ray absorptiometry (DXA; e.g., lower limb contracture \\> 15 degrees)\n* Inability to obtain free-flowing blood from a superficial forearm or hand vein\n* Pregnant women\n* Prisoners","70 Years",{"count":218,"type":21},40,[57],"The purposes of the study are to quantify and compare relationships among acute changes in inflammatory markers and evoked pain sensitivity after a high-fat meal (HFM) challenge, compared to a moderate-fat meal challenge, and explore the influence of body composition on these responses, in individuals with chronic spinal cord injury",[222,26],"Pain","2026-03-17",{"date":225,"type":36},"2026-03-19",{"date":227,"type":36},"2023-02-20",{"date":229,"type":21},"2027-08-31",{"name":231,"class":43},"University of Miami",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":240,"targetDuration":4,"studyType":55,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100550717","cerebral-and-anti-inflammatory-response-through-exercise---mechanisms-in-depressive-disorders-100550717","NCT06450704","Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders","Inflammatory and Brain Mechanisms and Clinical and Cognitive Effects of an Exercise Intervention in Major Depressive Disorder: a Randomised Longitudinal Clinical Trial.","CARE-MIND","Inclusion Criteria:\n\n* A diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria (through the Mini International Neuropsychiatric Interview (MINI)\n* Severity of depression according to the Hamilton Depression Rating Scale 17 items (HAM-D17): minimum of 14 cut-off score of moderate depression.\n* Outpatient clinical care.\n* Current antidepressant treatment that will be maintained during the 12 weeks of the physical exercise intervention.\n\nExclusion Criteria:\n\n* Diagnosis of any axis I diagnosis except for MDD;\n* Contraindications for Magnetic Resonance Imaging.\n* Antiinflammatory treatments or antibiotics within the week before randomisation.\n* Vaccines within the month before randomisation.\n* Fever (\\>38ºC) at the moment of study entry.\n* Pregnant women.\n* Alcohol or drug abuse.",{"count":241,"type":21},124,[57],"The goal of this clinical trial is to study how physical exercise works when applied to patients diagnosed with Major Depressive Disorder (MDD). The main questions it aims to answer are:\n\n* What are the antiinflammatory and oxidative stress and neural mechanisms involved in the antidepressant effects of exercise?\n* How effective is a physical exercise program in MDD patients in real-life conditions?\n\nThe experimental group will receive an exercise intervention as an add-on to their usual treatment (antidepressant treatment prescribed by the attending specialist). Researchers will compare to a control group, which will only receive standard treatment (antidepressant treatment prescribed by the attending specialist) and will be instructed to not change their usual physical activity. The aim is to see if a physical exercise intervention would induce a significant improvement in depressive symptoms and which mechanisms are responsible for this result.",[245,26],"Major Depressive Disorder",[245,247,248,249],"Physical Exercise","Inflammation","Neuroimaging","2026-01-05",{"date":252,"type":36},"2026-01-06",{"date":254,"type":36},"2025-04-21",{"date":256,"type":21},"2026-12-31",{"name":258,"class":43},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa",5,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":267,"targetDuration":4,"studyType":55,"phases":268,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":44},"100464088","phase-3-tranexamic-acid-in-traumatic-brain-injury-100464088","NCT05323149","Tranexamic Acid in Traumatic Brain Injury","The Impact of Early Use of Tranexamic Acid in Traumatic Brain Injury Upon the Inflammatory Response and Outcome","Inclusion Criteria:\n\n* Isolated traumatic brain injury patients (mild or moderate cases)\n* GCS \\> 8\n* non penetrating TBI in 8 hours onset\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Patient in cardiac arrest\n* Patients with coagulopathies\n* Renal failure patients\n* pregnancy\n* Patient refusal to participate",{"count":54,"type":21},[269],"PHASE3","In this study, our aim is to investigate the role of tranexamic acid for modulating the inflammation in patients with traumatic brain injury (TBI).",[26],"2025-12-27",{"date":274,"type":36},"2026-01-02",{"date":276,"type":36},"2022-05-18",{"date":278,"type":21},"2027-10-15",{"name":280,"class":43},"Assiut University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":289,"targetDuration":4,"studyType":55,"phases":291,"briefSummary":292,"conditions":293,"keywords":297,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":44},"100610797","effects-of-intraoperative-warming-methods-on-hematologic-inflammatory-indices-in-laparoscopic-cholecystectomy-100610797","NCT07232251","Effects of Intraoperative Warming Methods on Hematologic Inflammatory Indices in Laparoscopic Cholecystectomy","Evaluation of the Effects of Different Intraoperative Warming Techniques on Core Body Temperature and Hematologic Inflammatory Indices (SII, NLR, PLR, LMR) in Patients Undergoing Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Study","WARM-CHOL","Inclusion Criteria:\n\n* Patients scheduled for elective laparoscopic cholecystectomy.\n* ASA (American Society of Anesthesiologists) physical status I-III.\n* Age between 18 and 65 years.\n* Willingness and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* ASA IV-V patients.\n* Emergency surgery requirement.\n* Preoperative fever (\\>38.0 °C) or hypothermia (\\\u003C36.0 °C).\n* Operation duration \\\u003C60 minutes or \\>180 minutes.\n* Endocrine\u002Fmetabolic disorders affecting body temperature (e.g., moderate-severe thyroid dysfunction, pheochromocytoma, severe dysautonomia, malnutrition).\n* Active infection\u002Fsepsis or systemic infection within past 2 weeks.\n* Chronic immunosuppressive therapy (e.g., ≥10 mg\u002Fday prednisolone equivalent ≥2 weeks or biological agents in the past month).\n* Hematologic disorders (e.g., leukemia, aplastic anemia, myeloproliferative disorders) or abnormal blood counts (platelet \\\u003C100 ×10⁹\u002FL, leukocyte \\\u003C3 ×10⁹\u002FL).\n* Active malignancy or ongoing chemotherapy\u002Fradiotherapy in last 3 months.\n* Severe organ failure (Child-Pugh C liver, eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or dialysis, NYHA III-IV heart failure, GOLD III-IV COPD).\n* Coagulopathy or uncontrolled antithrombotic therapy.\n* Pregnancy or lactation.\n* Conversion from laparoscopic to open surgery.\n* Non-adherence to assigned warming protocol.\n* Inability to place esophageal temperature probe or unreliable temperature monitoring.\n* Intraoperative hemodynamic instability requiring prolonged vasopressor support or blood transfusion.\n* Missing or incomplete preoperative or postoperative CBC preventing calculation of inflammatory indices.\n* Withdrawal of consent or loss to follow-up.",{"count":290,"type":21},128,[57],"Perioperative hypothermia is a frequent and preventable complication that may cause adverse outcomes such as increased blood loss, impaired coagulation, and delayed recovery. Various active warming techniques are used to maintain normothermia during anesthesia; however, their comparative effects on systemic inflammatory responses remain unclear.\n\nThis randomized controlled clinical trial aims to evaluate the effects of different intraoperative warming methods on hematologic inflammatory indices - including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) - in patients undergoing elective laparoscopic cholecystectomy under general anesthesia.\n\nA total of eligible adult patients will be randomly assigned into four groups according to the intraoperative warming method applied:\n\nControl Group: No active warming applied.\n\nForced-Air Warming (FAW) Group: Warming blanket system used throughout surgery.\n\nFluid Warming (FW) Group: Intravenous fluids warmed to maintain normothermia.\n\nCombined Warming (FAW + FW) Group: Both forced-air and fluid warming applied simultaneously.\n\nCore body temperature and perioperative data will be recorded. Venous blood samples will be obtained preoperatively and 24 hours postoperatively to calculate inflammatory indices.\n\nThe primary objective is to determine whether active intraoperative warming techniques modulate postoperative inflammatory markers compared to no warming. Secondary outcomes include intraoperative temperature trends, recovery times, and the incidence of hypothermia-related complications.\n\nThe results are expected to identify the most effective warming strategy to minimize inflammation and optimize postoperative recovery in laparoscopic procedures.",[26,294,295,296],"Perioperative Hypothermia","Laparoscopic Cholecystectomy","Surgical Stress Response",[298,299,300,301,302,303,304,305,306,307,308],"Intraoperative warming","Forced-air warming","Combined warming","Hypothermia prevention","Fluid warming","Hematologic inflammatory indices","Neutrophil-to-lymphocyte ratio (NLR)","Platelet-to-lymphocyte ratio (PLR)","Systemic immune-inflammation index (SII)","Laparoscopic surgery","Cholecystectomy","2025-11-17",{"date":311,"type":36},"2025-11-19",{"date":313,"type":21},"2025-12-01",{"date":315,"type":21},"2026-04-02",{"name":317,"class":43},"Ataturk University",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":16,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":55,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":44},"100525153","phase-3-effect-of-colchicine-on-perioperative-anti-inflammatory-organ-injury-in-cardiac-surgery-100525153","NCT06118034","Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery","Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery : a Multi-center, Randomized, Controlled, Double-blind Clinical Trial","Inclusion criteria\n\n1. Aged between 50 and 80 years, male or female;\n2. Patients undergoing elective cardiac surgery;\n3. Have signed the informed consent form (ICF).\n\nExclusion criteria\n\n1. Patients undergoing emergency surgery;\n2. Patients undergoing deep hypothermic circulatory arrest surgery;\n3. Preoperative predicted mortality \\>3% according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II);\n4. Patients undergoing off-pump coronary artery bypass grafting (off-pump CABG) surgery;\n5. Patients undergoing left or right ventricular outflow tract obstruction surgery;\n6. Patients undergoing complex corrective surgery for congenital heart disease;\n7. Patients with an expected CPB exceeding 180 minutes or an anticipated aortic cross-clamp time exceeding 120 minutes;\n8. Patients expected to have a postoperative endotracheal tube removal time exceeding 24 hours;\n9. Patients with prolonged fasting or inability to self-feed;\n10. A history of malignant tumor;\n11. Patients with unstable preoperative vital signs requiring intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO)assistance, or endotracheal tube-assisted ventilation;\n12. A history of cardiac surgery;\n13. Patients with preoperative gastrointestinal symptoms, such as nausea, vomiting and diarrhea;\n14. Patients with a history of dialysis before surgery;\n15. Patients with a history of atrial fibrillation before surgery;\n16. Patients on long-term hepatorenal protective medications;\n17. Patients with hepatic and renal insufficiency (Child-Pugh class B or C, estimated glomerular filtration rate \\\u003C35 mL\u002Fmin\u002F1.73 m2);\n18. Patients with abnormal baseline inflammatory markers \\[interleukin-6 (IL6) \\>10 pg\u002FmL, procalcitonin (PCT) \\>0.5 ng\u002FmL, C reactive protein (CRP) \\>10 mg\u002FL\\];\n19. Patients diagnosed with infectious diseases, inflammatory immune diseases, or tumor;\n20. Patients who have received immunosuppressive or anti-inflammatory treatment;\n21. Patients allergic or intolerant to colchicine;\n22. Breastfeeding or pregnant women;\n23. Other situations deemed inappropriate for participation in the study by the investigator.","50 Years","80 Years",{"count":328,"type":21},768,[269],"All patients will be completed collection of demographic data, clinical data, and be observed for inflammatory organ damage, oxygenation index or SpO2\u002F FIO2, WBC, NEU, interleukin-1β, interleukin-6, interleukin-8 (IL-1β\u002F6\u002F8), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), procalcitonin (PCT), myoglobin (Myo), creatine kinase-MB (CK-MB), high-sensitivity cardiac troponin T (hs-cTnT), neutrophil elastase (NE), myeloperoxidase (MPO), APACHE II score, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, Murray lung injury score, serum creatinine, eGFR, mechanical ventilation time, ICU length of stay, drug-related gastrointestinal reactions, and 30-day and 90-day all-cause mortality, among other indicators.",[26,332],"Cardiac Disease","2025-11-13",{"date":309,"type":36},{"date":336,"type":36},"2024-01-28",{"date":338,"type":21},"2026-12-30",{"name":340,"class":43},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":326,"enrollmentInfo":348,"targetDuration":4,"studyType":55,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":364},"100427282","phase-4-immunoinflammatory-regulation-of-esketamine-in-septic-patients-100427282","NCT04843982","Immunoinflammatory Regulation of Esketamine in Septic Patients","Effects of Esketamine Combined With Propofol for Sedation on Systemic Inflammation and Immune Function in Septic Patients in the ICU: a Single-center, Non-blind, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years old ≤ age ≤60 years old;\n* SOFA score ≥2;\n* Mechanical ventilation should be required for at least 24 hours when included in the study;\n* Informed consent is obtained.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old or ≥ 60 years old;\n* Previous solid organ or bone marrow transplantation;\n* Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), or hematologic malignancies (leukemia and lymphoma, etc.);\n* Received radiotherapy or chemotherapy within the past 30 days, or received immunosuppressant drugs (tripterygium wilfordii, mycophenolate mofetil, cyclophosphamide, FK506, etc.), or continuous treatment with prednisolone more than 10 mg\u002Fday (or equivalent doses of the other hormones);\n* Unstable angina pectoris or myocardial infarction in the past six months;\n* Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, acute intracranial hemorrhage, acute intracranial infection, etc.);\n* Poorly controlled hypertension and congestive heart failure;\n* Increased intraocular or intracranial pressure;\n* Chronic kidney disease, received continuous renal replacement therapy in the past 30 days, or acute renal failure requiring CRRT;\n* Severe chronic liver disease (Child-Pugh class B or C);\n* Alcohol dependence, mental illness or severe cognitive impairment;\n* Pregnancy or lactation;\n* Informed consent is not obtained.",{"count":349,"type":21},100,[165],"Studies have shown that excessive systemic inflammatory response and concomitant immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is very important to reduce excessive inflammation and improve immunosuppression in the acute phase of sepsis. Clinical studies have shown that esketamine combined with propofol for sedation has been proven to be safe and effective for septic patients in the ICU due to its cardiovascular stability. Previous studies have demonstrated that esketamine has anti-inflammatory effects against depression and surgical stress. Our preliminary experimental studies have found that esketamine had strong anti-inflammatory effects in the acute phase of sepsis. However, it is not clear whether esketamine could reduce excessive inflammation and improve immunosuppression in septic patients primarily sedated with a continuous infusion of propofol.\n\nThis intervention study is to investigate whether three consecutive days of intravenous esketamine infusions via infusion pump (0.07 mg\u002Fkg\u002Fh) could reduce excessive inflammation and improve immunosuppression in septic patients requiring mechanical ventilation in the ICU under sedation primarily with propofol.",[353,25,26,354],"Esketamine","Immunosuppression",[353,25,26,354],"2025-07-17",{"date":358,"type":36},"2025-07-18",{"date":360,"type":36},"2021-07-28",{"date":362,"type":21},"2026-10-30",{"name":42,"class":43},2,{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":373,"targetDuration":4,"studyType":55,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":44},"100573347","hop-compounds-on-the-immune-system-in-overweight-people-100573347","NCT06745102","Hop Compounds on the Immune System in Overweight People","Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System in Overweight People With the Onset of Metabolic Diseases","ÜG","Inclusion Criteria:\n\n* BMI 25 - 29,9 kg\u002Fm²\n\nas well as one or more of the following incipient metabolic diseases:\n\n* pre-diabetes (fasting blood glucose 100-125 mg\u002FdL),\n* fatty liver (grade 1-3),\n* high-normal blood pressure to mild hypertension (grade 1, systolic 140-159 mmHg)\n\nExclusion Criteria:\n\n* History of diseases that could falsify the study results\n* inflammatory bowel diseases\n* malignant diseases of the gastrointestinal tract\n* food allergies\n* malabsorption\n* kidney or liver disease (except simple fatty liver)\n* symptomatic heart failure\n* Taking medication to treat these diseases\n* Consumption of special diets (e.g. vegan, gluten-free)\n* Pregnancy",{"count":374,"type":21},24,[57],"The aim of the present study is to determine the effect of Iso-alpha Acids and Xanthohumol from hops on the immune response in overweight participants.",[26],"2025-04-10",{"date":380,"type":36},"2025-04-15",{"date":382,"type":36},"2024-02-01",{"date":384,"type":21},"2025-12-30",{"name":386,"class":43},"University of Vienna",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":216,"enrollmentInfo":394,"targetDuration":4,"studyType":55,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":44},"100538116","hop-compounds-on-the-immune-system-vh-100538116","NCT06286644","Hop Compounds on the Immune System (VH)","Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System","Inclusion Criteria:\n\n* healthy\n* BMI: \\>18,5 kg\u002Fm² or \\\u003C30 kg\u002Fm²\n\nExclusion Criteria:\n\n* food intolerances\n* food allergies\n* chronic inflammatory diseases\n* metabolic diseases\n* viral or bacterial infections within the last 3 weeks of inclusion\n* intake of immunosuppressive medication",{"count":395,"type":21},14,[57],"The aim of the present study is to determine the effect of Iso-alpha-Acids and Xanthohumol from hops on the immune response of healthy participants over a timeframe of 6 hours.",[26],{"date":380,"type":36},{"date":401,"type":36},"2022-05-30",{"date":384,"type":21},{"name":386,"class":43},{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":412,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":55,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":429},"100549490","severe-covid-19-infection-in-children-presenting-to-eds-in-israel-and-england-100549490","NCT06434701","Severe COVID-19 Infection in Children Presenting to EDs in Israel and England","Severe COVID-19 Infection in Children Presenting to Emergency Departments in Israel and England: A Prospective Multicenter Study","SPICE","Inclusion Criteria:\n\n1. SACI\n\n   Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab testing or bronchoalveolar sample who meet the definition of SACI:\n   * Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal cannula, bilevel or continuous positive airway pressure machine, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Or\n   * Admitted to ICU\n2. MIS-C Patients aged 16 years or younger diagnosed with MIS-C","0 Years","16 Years",{"count":415,"type":21},500,[57],"Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.\n\nThe objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).\n\nA prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.",[419,26],"COVID-19","2025-03-11",{"date":422,"type":36},"2025-03-14",{"date":424,"type":36},"2024-09-30",{"date":426,"type":21},"2026-08-31",{"name":428,"class":43},"Hadassah Medical Organization",6,{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":55,"phases":440,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":44},"100557261","ketonifast-cyclic-enteral-daytime-feeding-with-ketogenic-nighttime-fasting-100557261","NCT06535815","KetoNiFast: Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting","KetoNiFast: Impact of Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting on Outcome of Critical Ill Patients.","KetoNiFast","Inclusion Criteria:\n\n* written informed consent to participate in this study\n* admission to ICU\n* enteral nutrition\n\nExclusion Criteria:\n\n* Severe liver dysfunction \u002F liver failure (Child Pugh \\>7 points \u002F category B)\n* Severe kidney dysfunction (KDIGO stage 3)\n* Total pancreatectomy \u002F insulin dependent diabetes mellitus (IDDM)\n* Pregnancy \u002F lactation\n* Hemoglobin concentration \\\u003C 80g\u002Fl\n* Severe metabolic disorders \u002F severe autoimmune diseases\n* Refractory metabolic or respiratory acidosis\n* Dysfunction of mitochondrial transport of fatty acids\n* Dysfunction of oxidation of fatty acids\n* Dysfunction of gluconeogenesis, production and reduction of ketones\n* Intermittent Porphyria\n* Severe cardiac arrhythmias \u002F cardiomyopathy\n* Contraindication against enteral nutrition\n* Lack of informed consent",{"count":439,"type":21},130,[57],"A physiological human nutrition includes circadian feeding and nighttime fasting during sleep. There is increasing evidence, that this natural fasting episode over nighttime majorly contributes to repair processes of the human body. So far, intensive care patients are normally enterally fed continuously, so that there is no circadian nutrition and no nighttime fasting. An enteral nutrition for 12 hours followed by a fasting period of 12 hours supported by exogenous ketone salts potentially improves the reconstitution of ICU patients compared to ICU patients who are continuously enterally fed.",[443,444,26],"Nutrition","Muscle Loss",[446,447,448],"Ketogenic diet","ketogenic fasting","cyclic enteral nutrition","2024-08-04",{"date":451,"type":36},"2024-08-06",{"date":453,"type":36},"2023-09-01",{"date":455,"type":21},"2026-03-01",{"name":457,"class":43},"University Hospital of Cologne",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":467,"conditions":468,"keywords":473,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":44},"100555555","cellular-immunity-neuroendocrine-and-inflammatory-factors-for-clinical-prognosis-in-acute-coronary-syndrome-100555555","NCT06513611","Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome","Identificación de la relación Entre Componentes de la Inmunidad Celular y Factores Inflamatorios y neuroendócrinos Como Determinantes Del pronóstico clínico en el síndrome Coronario Agudo","Inclusion Criteria:\n\n* Are over 21 years of age and admitted to the Coronary Unit of the Hospital de Clínicas with a diagnosis of Acute Coronary Syndrome (ACS).\n* Agree to participate in the study through informed consent.\n\nExclusion Criteria:\n\n* Concomitant diagnosis of chronic neoplastic or inflammatory disease.\n* Diagnosis of allergic disease, parasitic disease, asthma, or hypereosinophilic syndrome.\n* Severe associated valvular disease.\n* Acute myocardial infarction (AMI) in the previous month.\n* Chronic corticosteroid treatment.\n* Creatinine clearance \\\u003C30% by MDRD (Modification of Diet in Renal Disease).\n* Severe hepatic insufficiency.\n* Pregnant women.\n* Known disease that limits their life expectancy to 6 months.\n* Refuse to participate in the study either by their own will or unable to understand its characteristics due to their clinical condition.",{"count":466,"type":21},150,"In acute coronary syndrome (ACS), there is an increase in cortisol levels, as an expression of the stress response, and C-reactive protein, as an expression of the inflammatory response, which are in turn associated with changes in the components of cellular immunity, and ultimately are predictors of clinical events. The objective of this study is to demonstrate that, within the frame of reference of ACS, beyond the thrombotic phenomenon that leads to ischemia and myocardial necrosis, there is an activation of an inflammatory and stress response, evidenced by an elevation of CRP and cortisol, respectively, and sequentially modifications in the components of cellular immunity in peripheral blood that convey prognostic value during hospitalization and after discharge. A prospective, observational, analytical, unicentric study of consecutive patients with ACS, with telephone follow-up to 6 months, will be carried out. For 2 years, all eligible patients admitted with a diagnosis of ACS to the Coronary Care Unit of the Hospital de Clínicas José de San Martín in Buenos Aires will be registered consecutively.",[469,470,471,26,472],"Acute Coronary Syndrome","Stress Hyperglycemia","Cortisol; Hypersecretion","Coagulation",[474,475,476],"acute coronary syndrome","inflammation","cellular immunity","2024-07-16",{"date":479,"type":36},"2024-07-22",{"date":481,"type":36},"2024-01-01",{"date":33,"type":21},{"name":484,"class":43},"Hospital de Clinicas José de San Martín",{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":44},"100553890","clinical-outcomes-and-inflammatory-responses-in-viral-vs-bacterial-sepsis-100553890","NCT06491966","Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis","Comparative Analysis of Clinical Outcomes and Inflammatory Responses in Viral Versus Bacterial Sepsis: A Retrospective Cohort Study in ICU Patients","Inclusion Criteria:\n\n1. Patients diagnosed with sepsis according to Sepsis 3.0 criteria.\n2. Patients with confirmed bacterial sepsis based on positive bacterial cultures.\n3. Patients with confirmed viral sepsis, specifically COVID-19, diagnosed via RT-PCR for SARS-CoV-2 for viral group and negative for bacterial group.\n4. Patients aged 18 years and older.\n5. Patients admitted to the ICU during the study period.\n\nExclusion Criteria:\n\n1. Patients with mixed bacterial and viral infections.\n2. Patients with sepsis not meeting the Sepsis 3.0 criteria.\n3. Patients who received immunomodulatory therapies other than standard treatments (e.g., investigational drugs).\n4. Pregnant or breastfeeding women.","90 Years",{"count":494,"type":21},300,"This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis. Conducted at Sichuan Provincial People's Hospital, the study will retrospectively analyze data from ICU patients admitted between July 2021 and December 2023. The primary objective is to identify reliable biomarkers and diagnostic methods to improve patient outcomes through personalized diagnostic and therapeutic strategies.",[25,497,498,26,499,419,500],"Sepsis Bacterial","Viral Sepsis","Cytokine Storm","MODS","2024-07-08",{"date":503,"type":36},"2024-07-09",{"date":505,"type":36},"2024-04-02",{"date":507,"type":21},"2024-07-10",{"name":509,"class":43},"Sichuan Provincial People's Hospital",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":44},"100552070","combined-molecular-and-mechanistic-methods-for-detection-of-pressure-ulcers-100552070","NCT06468306","Combined Molecular and Mechanistic Methods for Detection of Pressure Ulcers","Combined Molecular and Mechanistic Methods for Early Detection and Individual Prevention of Pressure Ulcer Formation in Vulnerable Patients","Inclusion Criteria:\n\n\\- patients that use oronasal face masks in their ordinary care during routine management regimes of non invasive ventilation.\n\nExclusion Criteria\n\n* acute respiratory failure\n* previous ICU care\n* pressure ulcer on measurement site",{"count":466,"type":21},"This project aims to develop a novel method for identifying early tissue damage related to pressure ulcer (PU) development in vulnerable patients by measuring biomarkers of inflammation on the skin surface. PUs are common and costly injuries that result from prolonged pressure on the skin. Current methods to assess PU risk are unreliable, and the mechanisms of PU development are not well understood. This project contributes to new knowledge of PU etiology as well as the individual variability at a molecular level combined with new knowledge about nursing actions and clinical factors linked to PU progression and outcomes of prevention. The project will use non-invasive techniques and model-based analysis to identify specific biomolecules that reflect individual susceptibility to pressure exposure in different PU risk scenarios.",[520,26],"Pressure Ulcer",[520,522,523],"nursing","prevention","2024-06-20",{"date":526,"type":36},"2024-06-21",{"date":528,"type":21},"2024-08-01",{"date":530,"type":21},"2027-12-30",{"name":532,"class":533},"Linkoeping University","OTHER_GOV"]